AstraZeneca's BAXDROSTAT Trial Meets Primary Endpoint

TL;DR

AZN's BAXDROSTAT trial hits primary endpoint, good news for Cushing's syndrome patients.

AI Summary

AstraZeneca PLC announced on October 7, 2025, that its BAXDROSTAT Phase 3 trial, BAX24, met its primary endpoint. The trial evaluated BAXDROSTAT for the treatment of hypercortisolism in adults with Cushing's syndrome.

Why It Matters

This positive trial result is a significant step towards potential regulatory approval for BAXDROSTAT, offering a new treatment option for patients with Cushing's syndrome.

Risk Assessment

Risk Level: low — The filing is an informational report of a successful clinical trial outcome, which is generally positive news and does not introduce new immediate risks.

Key Players & Entities

• AstraZeneca PLC (company) — Registrant
• BAXDROSTAT (drug) — Investigational drug
• BAX24 (trial) — Phase 3 clinical trial name
• Cushing's syndrome (disease) — Condition being treated
• October 7, 2025 (date) — Filing date and announcement date

FAQ

From the Filing

0001654954-25-011529.txt : 20251007 0001654954-25-011529.hdr.sgml : 20251007 20251007063006 ACCESSION NUMBER: 0001654954-25-011529 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251007 FILED AS OF DATE: 20251007 DATE AS OF CHANGE: 20251007 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251378213 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a2843c.htm BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL a2843c   FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of October 2025   Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________       AstraZeneca PLC   INDEX TO EXHIBITS     1. Baxdrostat met primary endpoint in Bax24 Ph3 trial       7 October 2025   Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension   Baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in 24-hour ambulatory systolic blood pressure compared with placebo   Positive high-level results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Efficacy was observed throughout the 24-hour period, including early morning, when patients with hypertension are at a higher risk of cardiovascular events. 1-3   Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care. Baxdrostat was generally well tolerated, with a safety profile consistent with the BaxHTN trial. 4   There are 1.4 billion people worldwide living with hypertension. 5  In the US, approximately 50% of patients living with hypertension on multiple treatments do not have their blood pressure under control. 6  Consistent 24-hour blood pressure control is an important clinical outcome in patients with hard-to-control hypertension. 7-9  Multiple studies have demonstrated that 24-hour blood pressure is a more powerful predictor of cardiovascular events than a clinic-based meas